StockNews.com assumed coverage on shares of 22nd Century Group (NASDAQ:XXII – Free Report) in a research note released on Tuesday. The firm issued a sell rating on the biotechnology company’s stock.
22nd Century Group Trading Down 8.6 %
NASDAQ XXII opened at $0.17 on Tuesday. 22nd Century Group has a 1 year low of $0.15 and a 1 year high of $11.04. The company has a market cap of $1.38 million, a PE ratio of 0.00 and a beta of 1.39. The stock’s 50-day moving average price is $0.38 and its two-hundred day moving average price is $2.19.
22nd Century Group (NASDAQ:XXII – Get Free Report) last released its quarterly earnings results on Tuesday, August 13th. The biotechnology company reported ($0.36) earnings per share (EPS) for the quarter. 22nd Century Group had a negative net margin of 275.12% and a negative return on equity of 380.39%. The firm had revenue of $7.95 million for the quarter.
Institutional Investors Weigh In On 22nd Century Group
22nd Century Group Company Profile
22nd Century Group, Inc, a tobacco products company, engages in the sale and distribution of its own proprietary new reduced nicotine tobacco products. The company offers reduced nicotine content tobacco plants and very low nicotine combustible cigarette products. It also provides contract manufacturing services for conventional combustible tobacco products for third-party brands.
Featured Articles
- Five stocks we like better than 22nd Century Group
- Consumer Discretionary Stocks Explained
- MercadoLibre Targets Double-Digit Upside with Argentina Boom
- What is the Nasdaq? Complete Overview with History
- Domino’s Pizza Stock Delivers: A Hot Buy for Growth Investors
- Ride Out The Recession With These Dividend Kings
- 3 Small-Cap Stocks Ready to Deliver Significant Growth
Receive News & Ratings for 22nd Century Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 22nd Century Group and related companies with MarketBeat.com's FREE daily email newsletter.